RegeneRx Biopharmaceuticals, Inc. is a clinical-stage, virtual biopharmaceutical company primarily focused on the discovery and development of novel molecules designed to accelerate tissue and organ repair, protection, and regeneration. Based in Rockville, Maryland, USA, the company???s entire operational focus is centered around therapeutic candidates derived from a single active molecule: Thymosin beta 4 (T?4), a naturally occurring, regenerative peptide.
Core Business and Scientific Focus
RegeneRx's central mission is to translate the proven regenerative capabilities of Thymosin beta 4 (T?4) into pharmaceutical products for various diseases and injuries. T?4 is a naturally occurring amino acid peptide with diverse biological activities, including the promotion of cell migration, cytoprotection, wound healing, and anti-inflammatory effects. The company structures its operations around a single business segment: the development and marketing of these T?4-based product candidates.
The company operates a virtual business model, meaning it relies heavily on strategic partnerships, licensing agreements, and joint ventures to advance its product pipeline without significant in-house manufacturing or large-scale clinical operation costs. RegeneRx maintains active partnerships and licensing agreements in four major territories: the U.S. and Canada, China, Pan Asia (including Korea and Japan), and the European Union. A notable example of this strategy is the U.S. joint venture, ReGenTree LLC, established with HLB Therapeutics, a Korean biopharmaceutical company, which is sponsoring the clinical development of the company's lead ophthalmic drug candidate in the U.S. and bearing the associated development costs.
Products and Services Pipeline
RegeneRx has formulated T?4 into three distinct drug candidates, each targeting a different administration route and therapeutic area. These represent the company's entire product pipeline in clinical development.
Ophthalmic Product
RGN-259
Description: A sterile, preservative-free, topical eye drop.
Indication: Developed for the regeneration of corneal tissues damaged by injury, disease, or other pathology. The primary focus is on treating ophthalmic indications such as Neurotrophic Keratitis (NK), which is an orphan indication, and Dry Eye Disease (DED).
Development Stage: RGN-259 is the most advanced candidate, currently in Phase 3 clinical trials in the U.S. and EU for the treatment of NK.
Systemic Product
RGN-352
Description: An injectable formulation designed for systemic administration.
Indication: Intended to treat a broad range of conditions that would benefit from the systemic administration of T?4, including cardiovascular diseases, and diseases of the central and peripheral nervous systems.
Dermal Product
RGN-137
Description: A topical gel formulation.
Indication: Developed for treating dermal wounds and promoting the reduction of scar tissue.
Services (Licensing and Partnerships)
As a virtual biopharmaceutical company, RegeneRx's primary service and source of revenue is the out-licensing of its Thymosin beta 4 technology and drug candidates. This involves:
Technology Licensing: Granting rights to its T?4-based compounds for development and commercialization in specific geographic territories or for specific indications.
Joint Venture Formation: Creating alliances, such as ReGenTree LLC, where the partner funds and manages the clinical development in exchange for commercial rights in defined markets, minimizing financial risk for RegeneRx.
This operational model allows RegeneRx to focus on the scientific foundation of T?4 and its therapeutic potential while leveraging the resources and market presence of its partners for clinical development and eventual commercialization across various global markets.
Please note: This information is generated by AI. For legal use, verify with company sources.
